JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut

Key Takeaways Jazz Pharmaceuticals (JAZZ) reported second-quarter 2025 adjusted loss of $8.25 per share, wider than the Zacks Consensus Estimate of a loss of $6.12. This downtick was primarily due to a one-time charge incurred by the company for the acquisition of clinical-stage biotech Chimerix, completed in April, which impacted the bottom line by $14.75 per share. In the year-ago period, the company reported adjusted earnings per share (EPS) of $5.25. Total revenues rose 2% year over year to $1.05 billio ...